Cargando…
Targeting IL-6 Trans-Signaling: Amplifying the Benefits of IL-6 Inhibition in Myocardial Infarction
[Figure: see text]
Autores principales: | Aukrust, Pål, Kleveland, Ola, Gullestad, Lars |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165105/ https://www.ncbi.nlm.nih.gov/pubmed/34102669 http://dx.doi.org/10.1016/j.jacbts.2021.01.007 |
Ejemplares similares
-
IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction
por: Orrem, Hilde L., et al.
Publicado: (2018) -
Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction
por: Ueland, Thor, et al.
Publicado: (2018) -
Selective Interleukin-6 Trans-Signaling Blockade Is More Effective Than Panantagonism in Reperfused Myocardial Infarction
por: George, Marc Jonathan, et al.
Publicado: (2021) -
Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST‐Segment–Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform
por: George, Marc J., et al.
Publicado: (2020) -
Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction
por: Helseth, Ragnhild, et al.
Publicado: (2021)